The Importance of Pseudo Thrombocytopenia Due to Platelet Cold Agglutination before Surgery, What Should We Do? A Case Report.

Platelet cold agglutination (PCA) is a rare in-vitro phenomenon caused by Immunoglobulin M (IgM) autoantibodies, which results in Ethylenediaminetetraacetic Acid (EDTA) independent pseudo thrombocytopenia (PTCP). Its diagnosis is made based on the peripheral blood smear (PBS) examination and pre-test warming blood sample. Here, a case of PTCP secondary to PCA is presented.

Reporting two hemoglobin J Iran cases, molecular follow-up, or is it insignificant?

Background: Hemoglobin J is one of the fast hemoglobin that has a more negative charge due to β77His→Asp substitution. Acquisition of this hemoglobin is not associated with any specific clinical sign, but the combination of this hemoglobinopathy with beta-thalassemia and other hemoglobinopathies can cause challenges.

Case Presentation: In this article, two cases with hemoglobin J are introduced; the first patient for premarital testing and the other for his fatigue.

Agitation-dependent biomechanical forces modulate GPVI receptor expression and platelet adhesion capacity during storage.

Background: Continuous agitation during storage slows down the platelet storage lesions. However, in special circumstances, manual-mixing can be alternatively used to store products for short time periods without compromising platelet quality. Based on this finding, and given the role of shear stress in modulating receptor expression, we were interested in comparing the levels of platelet adhesion receptor, GPVI and platelet adhesion capacity under each storage condition.

Reducing state attenuates ectodomain shedding of GPVI while restoring adhesion capacities of stored platelets: evidence addressing the controversy around the effects of redox condition on thrombosis.

Thrombosis involves different stages including platelet adhesion to the site of injury, aggregatory events governed by integrin activation, pro-inflammatory responses recruiting leukocytes and finally, pro-coagulant activity which results in fibrin generation and clot formation. As important signaling agents, reactive oxygen species (ROS) reduce thrombus volume and growth, however given such a multistage mechanism, it is not well-elucidated how ROS inhibition modulates thrombosis. PRP-platelet concentrates (PCs) were either treated with ROS-reducing agents (1 mM NAC or 30 μM NOX inhibitor, VAS2870) or kept untreated during storage.